Practical Considerations in Multiple Myeloma: Optimizing Therapy with New Proteasome Inhibitors
Release Date: November 28, 2016
Expiration Date: November 28, 2017
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity will focus on how new proteasome inhibitors may be safely and effectively incorporated into clinical practice for the management of patients with multiple myeloma. Practical aspects of optimizing therapy with these agents will be addressed, including patient selection, compliance, and side-effect management, as well as guidelines on differentiating between available proteasome inhibitors in clinical practice.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills incorporating new proteasome inhibitors for patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Identify and differentiate between the new proteasome inhibitors for multiple myeloma
- Summarize patient selection approaches for each new proteasome inhibitor
- Outline practical considerations for utilizing the proteasome inhibitors in practice
Practical Considerations in Multiple Myeloma: Optimizing Therapy with New Proteasome Inhibitors – R. Donald Harvey III, PharmD, BCOP, FCCP, FHOPA
Instructions for Participation and Credit
This activity is eligible for credit through November 28, 2017. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
R. Donald Harvey III, PharmD, BCOP, FCCP, FHOPA
Department of Pharmacology
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Dr. R. Donald Harvey received his doctor of pharmacy degree from the University of North Carolina (UNC) at Chapel Hill. He completed a hematology/oncology specialty residency at UNC Hospitals and School of Pharmacy, and a pharmacy practice residency at the University of Kentucky Medical Center and College of Pharmacy. Dr. Harvey is an Associate Professor in the Department of Pharmacology and the Department of Hematology and Medical Oncology at Emory University School of Medicine. In addition, he is Director of the Phase I Clinical Trials Section at the Winship Cancer Institute of Emory University in Atlanta, Georgia.
Dr. Harvey is a board certified pharmacotherapy specialist and oncology pharmacist, and a fellow of the Hematology/Oncology Pharmacy Association. He holds membership in the American Society of Pharmacometrics, American Society for Clinical Pharmacology and Therapeutics, International Society of Oncology Pharmacy Practitioners, American Association for Cancer Research, American Society of Hematology, American Society of Clinical Oncology, Hematology-Oncology Pharmacists Association, American College of Clinical Pharmacy, and the American Society of Health-System Pharmacists. Dr. Harvey is on the editorial board of the Journal of Oncology Pharmacy Practice and Pharmacotherapy, and is section editor of original research for the Journal of Hematology Oncology Pharmacy. In addition, he is a manuscript reviewer for the British Journal of Clinical Pharmacology, Clinical Cancer Research, Investigational New Drugs, Journal of Oncology Pharmacy Practice, British Journal of Cancer, Transfusion, Annals of Oncology, Cancer, Journal of Clinical Pharmacology, and Pharmacotherapy, among others. Dr. Harvey’s research focuses on the application of clinical pharmacology principles to improve cancer treatment outcomes.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-121-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. R. Donald Harvey has received honoraria as a consultant from Bristol-Myers Squibb Company and Takeda Oncology. He has received grant support related to research activities from Acetylon Pharmaceuticals, Inc., Amgen Inc., Bristol-Myers Squibb, Calithera BioSciences, Inc., Celgene Corporation, Cleave Biosciences, Novartis AG, and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Physician Payments, Sunshine Act
MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Celgene Corporation, and Takeda Oncology.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.